Biogen Inc. $BIIB Shares Sold by Vinva Investment Management Ltd

Vinva Investment Management Ltd lessened its stake in Biogen Inc. (NASDAQ:BIIB) by 34.2% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 38,704 shares of the biotechnology company’s stock after selling 20,158 shares during the quarter. Vinva Investment Management Ltd’s holdings in Biogen were worth $5,361,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Elevation Point Wealth Partners LLC purchased a new stake in shares of Biogen during the second quarter worth approximately $25,000. Rothschild Investment LLC lifted its stake in Biogen by 64.7% in the second quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 88 shares during the last quarter. Accredited Wealth Management LLC grew its holdings in Biogen by 1,233.3% during the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 185 shares in the last quarter. WFA of San Diego LLC acquired a new position in Biogen during the 2nd quarter worth approximately $32,000. Finally, True Wealth Design LLC increased its position in shares of Biogen by 62.9% in the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 90 shares during the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Biogen

In other Biogen news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the transaction, the insider directly owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.18% of the company’s stock.

Analyst Ratings Changes

BIIB has been the topic of a number of analyst reports. Royal Bank Of Canada raised their price objective on shares of Biogen from $217.00 to $233.00 and gave the company an “outperform” rating in a report on Monday, February 9th. HSBC reiterated a “reduce” rating and set a $143.00 target price (down from $144.00) on shares of Biogen in a research note on Wednesday, December 10th. Morgan Stanley set a $190.00 price target on Biogen in a research note on Sunday, February 8th. Tudor Pickering set a $201.00 price target on Biogen in a report on Monday, February 9th. Finally, Citigroup upped their price objective on Biogen from $185.00 to $215.00 and gave the stock a “neutral” rating in a research report on Monday, February 9th. Twelve investment analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $205.04.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen will present new spinal muscular atrophy (SMA) data, including long‑term high‑dose nusinersen results and Phase 1b salanersen data as Phase 3 studies begin — news that supports the company’s SMA pipeline and could boost long‑term revenue potential if later trials read out favorably. Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
• Positive Sentiment: The New England Journal of Medicine published first data suggesting disease‑modifying potential for zorevunersen (Stoke Therapeutics collaboration) in Dravet syndrome, supporting the ongoing global Phase 3 EMPEROR study — a favorable scientific read that can increase confidence in Biogen’s partnered pipeline assets. The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
• Positive Sentiment: Proposed legislation (H.R. 7336, the ALS Better Care Act) would expand Medicare coverage and payments for ALS‑related services and incentivize clinical trial participation — a policy tailwind that could improve access and reimbursement for ALS therapies and indirectly benefit Biogen’s neurology franchise. New Bill: Representative Janice D. Schakowsky introduces H.R. 7336: ALS Better Care Act
• Neutral Sentiment: Analyst / investor pieces and fund letters have highlighted Biogen as an attractive long‑term holding (coverage in InsiderMonkey/Yahoo) — supportive for investor interest but not an immediate catalyst. What Makes Biogen (BIIB) an Attractive Long-Term Holding?
• Neutral Sentiment: Recent short‑interest reports show anomalous data (zero shares / NaN increases and a days‑to‑cover of 0.0), indicating reporting noise rather than a clear short‑selling pressure signal — treat these items as unreliable until clarified. (Internal short‑interest entries)
• Negative Sentiment: Despite positive pipeline and data releases, shares are down today — likely reflecting profit‑taking after recent gains, thin trading (volume below recent average), and market focus on near‑term revenue/guidance rather than later‑stage trial data. No new negative company‑specific regulatory or financial disclosures were reported in the entries provided.

Biogen Price Performance

Shares of NASDAQ BIIB opened at $184.87 on Monday. The stock has a market cap of $27.13 billion, a P/E ratio of 20.98, a P/E/G ratio of 1.47 and a beta of 0.15. Biogen Inc. has a twelve month low of $110.04 and a twelve month high of $202.41. The stock has a 50 day moving average of $183.08 and a two-hundred day moving average of $165.46. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last announced its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. The business had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The company’s revenue for the quarter was down 7.2% compared to the same quarter last year. During the same period last year, the firm posted $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, research analysts forecast that Biogen Inc. will post 15.83 earnings per share for the current year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.